Omega Therapeutics Inc (NASDAQ:OMGA) has a beta value of 1.65 and has seen 6.99 million shares traded in the last trading session. The company, currently valued at $27.30M, closed the last trade at $0.49 per share which meant it gained $0.05 on the day or 11.23% during that session. The OMGA stock price is -810.2% off its 52-week high price of $4.46 and 10.2% above the 52-week low of $0.44. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.35 million shares traded. The 3-month trading volume is 304.08K shares.
The consensus among analysts is that Omega Therapeutics Inc (OMGA) is Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.26.
Omega Therapeutics Inc (NASDAQ:OMGA) trade information
Sporting 11.23% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the OMGA stock price touched $0.49 or saw a rise of 26.87%. Year-to-date, Omega Therapeutics Inc shares have moved -33.87%, while the 5-day performance has seen it change -1.38%. Over the past 30 days, the shares of Omega Therapeutics Inc (NASDAQ:OMGA) have changed -40.75%. Short interest in the company has seen 6.36 million shares shorted with days to cover at 16.34.
Wall Street analysts have a consensus price target for the stock at $9, which means that the shares’ value could jump 94.56% from current levels. The projected low price target is $7.0 while the price target rests at a high of $11.0. In that case, then, we find that the current price level is -2144.9% off the targeted high while a plunge would see the stock gain -1328.57% from current levels.
Omega Therapeutics Inc (OMGA) estimates and forecasts
Figures show that Omega Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -74.32% over the past 6 months, with this year growth rate of 33.89%, compared to 16.40% for the industry. Revenue growth from the last financial year stood is estimated to be 175.79%.
5 analysts offering their estimates for the company have set an average revenue estimate of 1.12M for the current quarter. 5 have an estimated revenue figure of 700.8k for the next ending quarter. Year-ago sales stood 989k and 2.36M respectively for this quarter and the next, and analysts expect sales will grow by 13.33% for the current quarter and 175.79% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -48.08% over the past 5 years.
OMGA Dividends
Omega Therapeutics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Omega Therapeutics Inc (NASDAQ:OMGA)’s Major holders
Insiders own 1.62% of the company shares, while shares held by institutions stand at 90.43% with a share float percentage of 91.92%. Investors are also buoyed by the number of investors in a company, with Omega Therapeutics Inc having a total of 70.0 institutions that hold shares in the company. The top two institutional holders are FLAGSHIP PIONEERING INC. with over 29.23 million shares worth more than $60.5 million. As of 2024-06-30, FLAGSHIP PIONEERING INC. held 52.9924% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 6.24 million shares as of 2024-06-30. The firm’s total holdings are worth over $12.92 million and represent 11.3181% of shares outstanding.
